Showing 1351-1360 of 1735 results for "".
- Quantel Medical Launches Dry Eye Information Website for Patientshttps://modernod.com/news/quantel-medical-launches-dry-eye-information-website-for-patients/2479085/Quantel Medical has launched
- Hadley Launches New Website For Those Facing Vision Losshttps://modernod.com/news/hadley-launches-new-website-for-those-facing-vision-loss/2478068/In 1920, William Hadley, a Chicago area high school teacher who lost his sight at the age of 55, revolutionized the way adults facing vision loss would learn to read again when he created his Braille by Mail system. One hundre
- Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-Based Point-of-Care (T-POC) Quantitative Testing Platformhttps://modernod.com/news/versea-ophthalmics-commences-phase-1-launch-of-novel-tear-based-point-of-care-t-poc-quantitative-testing-platform/2481745/Verséa Ophthalmics announced the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow Readers. T-POC TOTAL IgE Immunoassay Kit is a new quantitative point-of-care test used in the diagnosis and management o
- Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIIIhttps://modernod.com/news/oyster-point-pharma-to-present-new-scientific-analyses-at-world-cornea-congress-viii/2481117/Oyster Point Pharma announced it will present new scientific analyses at World Cornea Congress VIII, which is taking place in Chicago from September 28-29, 2022. “We look forward to presenting our post-hoc analyses on the clini
- Oyster Point Pharma Announces Tyrvaya Nasal Spray Now Covered by Express Scriptshttps://modernod.com/news/oyster-point-pharma-announces-tyrvaya-nasal-spray-now-covered-by-express-scripts/2480656/Oyster Point Pharma announced Tyrvaya Nasal Spray’s placement on the Express Scripts National Preferred, Basic, and High Performance Formularies, which collectively covers an estimated 26 million people, effective February 19, 2022. Tyrvaya is the first and only na
- Oyster Point Pharma Expands Executive Leadership Team to Support Commercialization of Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-expansion-of-executive-leadership-team-to-support-commercialization-of-tyrvaya-nasal-spray/2480475/Oyster Point Pharma announced the promotion of Barry Rosenfeld, JD, as General Counsel; and Raegan A. McClain, JD, LLM, CCEP, as Chief Compliance Officer, both of whom will join the executive leadership team. “We are thrilled to expand our executive
- Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-publication-in-ophthalmology-of-onset-2-phase-3-data-on-tyrvaya-varenicline-solution-nasal-spray/2480446/Oyster Point Pharma announced that results from the multicenter, randomized, double-masked, vehicle-controlled phase 3 clinical trial (The ONSET-2 study) of Tyrvaya Nasal Spray (varenicline solution) have been published in Ophthalmology.1 
- Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021https://modernod.com/news/oyster-point-pharma-to-present-data-at-the-american-academy-of-ophthalmology-annual-meeting-2021/2480417/Oyster Point Pharma announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) annual meeting 2021 being held in New Orleans, November 12–15, 2021. “The American Academy of Ophthalmology is the world’
- Oyster Point’s Tyrvaya Nasal Spray for Dry Eye Disease is Now Available at US Regional Wholesalershttps://modernod.com/news/oyster-points-tyrvaya-nasal-spray-for-dry-eye-disease-is-now-available-at-us-regional-wholesalers/2480399/Oyster Point Pharma announced that Tyrvaya (varenicline solution) Nasal Spray 0.03 mg is now available at US regional wholesalers for distribution to pharmacies. The FDA approved Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease on O
- Oyster Point Pharma Receives FDA Approval of Tyrvaya Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-receives-fda-approval-of-tyrvaya-nasal-spray-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2480356/Oyster Point Pharma announced that the FDA has approved Tyrvaya (varenicline solution) Nasal Spray 0.03 mg for the treatment of the signs and symptoms of dry eye disease. The approval marks the first and only nasal spray approved for the treatment of dry eye disease. Tyrvaya&n